[144] Amneal Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. (AMRX) Form 144 indicates a proposed sale of 84,036 common shares through Charles Schwab, with an aggregate market value of $818,930.82. The filing lists approximately 314,079,309 shares outstanding and an approximate sale date of 08/22/2025 on NASDAQ. The securities were acquired on 07/05/2018 as executive compensation. The filing also discloses two recent sales by the named person: 71,694 shares sold on 08/14/2025 for $666,037.26 and 50,000 shares sold on 08/12/2025 for $452,030.89. The signer represents they are not aware of any undisclosed material adverse information about the issuer.

Positive

• None.

Negative

• Proposed insider sale of 84,036 common shares (aggregate value $818,930.82) is disclosed
• Recent dispositions reported: 71,694 shares sold (08/14/2025) for $666,037.26 and 50,000 shares sold (08/12/2025) for $452,030.89

Insights

Securities Analyst

TL;DR: Routine insider notice of proposed sale; discloses acquisition as compensation and recent sales, no new financial metrics provided.

The Form 144 is a standard compliance filing showing an insider or related person intends to sell 84,036 Amneal common shares via Charles Schwab with an aggregate market value of $818,930.82 and cites past sales of 71,694 and 50,000 shares in August 2025. The securities were acquired as executive compensation on 07/05/2018. This filing does not provide operating results, guidance, or new corporate events; it documents planned liquidity by a holder and past dispositions as required under Rule 144.

Corporate Governance Specialist

TL;DR: Disclosure fulfills Rule 144 requirements; contains no indication of undisclosed adverse information by the signer.

The notice includes the required representation that the seller is unaware of undisclosed material adverse information and lists the broker, proposed sale date, and share counts. It confirms the shares were acquired as executive compensation in 2018. From a governance perspective this is a procedural disclosure documenting insider sales activity rather than a corporate action or governance change.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab Corp. 3000 Schwab Way Westlake TX 76262	84036	818930.82	314079309	08/22/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/05/2018	Executive Compensation	Issuer			84036	07/05/2018	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
NIKITA SHAH 400 CROSSING BLVD BRIDGEWATER NJ 08807	Common	08/14/2025	71694	666037.26
NIKITA SHAH 400 CROSSING BLVD BRIDGEWATER NJ 08807	Common	08/12/2025	50000	452030.89

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Amneal (AMRX) Form 144 disclose?

The Form 144 states a proposed sale of 84,036 common shares through Charles Schwab with an aggregate market value of $818,930.82 and an approximate sale date of 08/22/2025.

Who acquired the shares and how were they acquired?

The securities were acquired on 07/05/2018 as executive compensation, with the amount listed as 84,036 shares.

Were there recent sales by the reporting person?

Yes. The filing lists sales by the named person of 71,694 shares on 08/14/2025 (gross proceeds $666,037.26) and 50,000 shares on 08/12/2025 (gross proceeds $452,030.89).

On which exchange will the proposed sale occur?

The filing lists NASDAQ as the securities exchange for the approximate sale date of 08/22/2025.

Does the filer assert any undisclosed material information?

By signing, the person represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.